Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener klinische Wochenschrift
Erschienen in:

01.07.2014 | case report

Dornase alpha inhalations as a treatment option for recurrent lower respiratory tract infections in a child with Sotos syndrome

verfasst von: Philipp Eickhoff, MD, Tamas Fazekas, MD, Hans Wank, MD, Ulrike Kastner, MD

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 13-14/2014

Einloggen, um Zugang zu erhalten

Summary

Recurrent episodes of lower respiratory tract infections (LRTIs) are a rare complication of muscular hypotonia in patients with Sotos syndrome. We report on a male child suffering from repeated LRTIs including bronchitis, pneumonia, and atelectasis during infancy despite inhalations with salbutamol and fluticasone combined with manual chest percussion therapy. After initiation of dornase alpha inhalations in addition to the current treatment, we observed an improvement in the respiratory symptoms as well as a reduction in the rate of hospitalizations and in the occurrence of LRTIs. We assume that dornase alpha inhalations, in combination with airway clearance techniques, reduced the viscosity of airway secretions and by this improved mucociliary clearance and coughing efficiency.
Vorheriger Artikel Severe Clostridium difficile infection: incidence and risk factors at a tertiary care university hospital in Vienna, Austria
Nächster Artikel Allergic reaction to suxamethonium during emergency caesarean section and pseudocholinesterase deficiency in the same patient
Literatur
1.
Sotos JF, Dodge PR, Muirhead D, et al. Cerebral gigantism in childhood. N Engl J Med. 1964;271:109–16.PubMedCrossRef
2.
3.
Schramm CM. Current concepts of respiratory complications of neuromuscular disease in children. Curr Opin Pediatr. 2000;12:203–7.PubMedCrossRef
4.
Rogers DF. Mucoactive agents for airway mucus hypersecretory diseases. Respir Care. 2007;52(9):1176–97.PubMed
5.
Anon. Summary of product characteristics: Pulmozyme. Hertfordshire, Roche Products Limited; 1996.
6.
Finder JD. Airway clearance modalities in neuromuscular disease. Paediatr Respir Rev. 2010;11:31–34.PubMedCrossRef
7.
8.
De Boeck K, Vermeulen F, Vreys M, et al. Airway clearance techniques to treat acute respiratory disorders in previously healthy children: where is the evidence? Eur J Pediatr. 2008;167:607–12.PubMedCrossRef
9.
Boitano LJ. Management of airway clearance in neuromuscular disease. Respir Care. 2006;51(8):913–22.PubMed
10.
Kravitz RM. Airway clearance in duchenne muscular dystrophy. Pediatrics. 2009;123:S231–5.CrossRef
11.
Boogaard R, de Jongste JC, Merkus P. Pharmacotherapy of impaired mucociliary clearance in non-CF pediatric lung disease. A review of the literature. Pediatr Pulmonol. 2007;42:989–1001.PubMedCrossRef
12.
Smyth AR, Barbato A, Beydon N, et al. Respiratory medicines for children: current evidence, unlicensed use and research priorities. Eur Respir J. 2010;35:247–65.PubMedCrossRef
13.
Lesic I, Maurer E, Strippoli MP, et al. Primäre Ziliendyskinesie in Österreich. Wien Klin Wochenschr. 2009;121:616–22.PubMedCrossRef
14.
15.
Eickhoff P, Fazekas T, Pötschger U, et al. Effect of treatment with dornase alpha on outcome of late-onset non-infectious pulmonary complications after paediatric allogeneic haematopoietic stem cell transplantation. Bone Marrow Transpl. 2010;45:S1–77.CrossRef
16.
Christopher F, Chase D, Stein K, Milne R. rhDNase therapy for the treatment of cystic fibrosis patients with mild to moderate lung disease. J Clin Pharm Ther. 1999;24:415–26.PubMedCrossRef
17.
Panitch HB. Respiratory issues in the management of children with neuromuscular disease. Respir Care. 2006;51(8):885–95.PubMed
18.
McKenzie SG, Chowdhury S, Strandvik B, et al. Dornase alfa is well tolerated: data from the epidemiologic registry of cystic fibrosis. Pediatr Pulmonol. 2007;42:928–37.PubMedCrossRef
Metadaten
Titel
Dornase alpha inhalations as a treatment option for recurrent lower respiratory tract infections in a child with Sotos syndrome
verfasst von
Philipp Eickhoff, MD
Tamas Fazekas, MD
Hans Wank, MD
Ulrike Kastner, MD
Publikationsdatum
01.07.2014
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 13-14/2014
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-014-0552-2

Weitere Artikel der Ausgabe 13-14/2014

Endovascular treatment of delayed hemorrhage developing after the pancreaticoduodenectomy procedure

  • original article

Severe Clostridium difficile infection: incidence and risk factors at a tertiary care university hospital in Vienna, Austria

  • short report

Erratum to: Primary anterior cruciate ligament reconstruction in athletes: a 5-year follow up comparing patellar tendon versus hamstring tendon autograft

  • Erratum

Allergic reaction to suxamethonium during emergency caesarean section and pseudocholinesterase deficiency in the same patient

  • case report

MUW researcher of the month

  • MUW researcher of the month

May mean platelet volume levels be a predictor in the diagnosis of pelvic inflammatory disease?

  • original article